Heron Therapeutics, Inc.
HRTX
$0.84
-$0.03-3.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.22% | 2.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.22% | 2.72% | |||
| Cost of Revenue | -77.45% | 20.27% | |||
| Gross Profit | 62.60% | -6.47% | |||
| SG&A Expenses | -4.59% | 3.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.15% | 8.93% | |||
| Operating Income | 100.93% | -150.03% | |||
| Income Before Tax | 83.12% | -634.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 83.12% | -634.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 83.12% | -634.78% | |||
| EBIT | 100.93% | -150.03% | |||
| EBITDA | 116.53% | -238.99% | |||
| EPS Basic | 84.71% | -562.58% | |||
| Normalized Basic EPS | 62.83% | -132.99% | |||
| EPS Diluted | 84.71% | -413.50% | |||
| Normalized Diluted EPS | 62.83% | -132.99% | |||
| Average Basic Shares Outstanding | 10.38% | 10.60% | |||
| Average Diluted Shares Outstanding | 10.38% | 10.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||